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Edited by Beat ImhofAbstract Pemphigus vulgaris (PV) is an autoimmune disease
characterized by binding of IgG autoantibodies to epidermal
keratinocyte desmosomes. IgG autoantibodies obtained from a
patient with mucocutaneous PV reacted with plakoglobin (Plkg)
in addition to desmoglein-3 (Dsg3) and Dsg1. Immunoﬂuores-
cence analysis conﬁrmed that IgG autoantibodies, unlike anti-
bodies from a healthy volunteer, caused disruption of cell–cell
contacts in HaCaT keratinocytes. Moreover, apoptosis was
enhanced in cells treated with autoantibodies compared to those
treated with normal antibodies. The apoptotic process induced by
IgG autoantibodies was characterized by caspase-3 activation,
Bcl-2 depletion and Bax expression. The present report demon-
strates that PV IgG autoantibodies promote apoptosis in HaCaT
keratinocytes.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Pemphigus vulgaris (PV) is a bullous autoimmune disease of
the mucocutaneous surfaces, characterized histologically by
suprabasal acantholytic vesicles caused by the separation of
epidermal cells. Immunoﬂuorescence (IF) studies have dem-
onstrated the presence of autoantibodies in epidermal lesions
and in the serum of PV patients [1]. Impaired intercellular
adhesion in PV seems to be due to binding of autoantibodies
directed to the desmosomal transmembrane protein desmog-
lein-3 (Dsg3), a glycoprotein of the cadherin family of adhe-
sion molecules [2]. It has also been described that PV patients
can develop IgG antibodies against Dsg1 [3] and other anti-
gens [4]. These autoantibodies have been shown to be patho-
genic, since they are able to induce acantholysis in neonatal
mice in passive transfer experiments [5,6].
Apoptosis is an important homeostatic mechanism that
maintains correct cell numbers in tissues by balancing cell
proliferation with cell death [7]. Epidermis is continuously* Corresponding author. Fax: +34-48-425649.
E-mail address: mjlopez@unav.es (M.J. Lopez-Zabalza).
Abbreviations: PV, pemphigus vulgaris; Dsg, desmoglein; IF, immu-
noﬂuorescence; DMEM, Dulbecco’s modiﬁed Eagle’s medium; PBS,
phosphate buﬀered saline; ELISA, enzyme-linked immunoadsorbent
assay
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the most important factors controlling cell growth and apop-
tosis in keratinocytes. It is now clear that loss of anchorage
may cause apoptosis in epithelial cells [8,9], but little is known
about regulation of apoptosis by cadherin-mediated cell–cell
adhesion [10]. However, there is evidence indicating that dis-
ruption of cell–cell contacts in acantholytic skin diseases may
in some cases provoke apoptosis of keratinocytes [11]. More-
over, previous studies have demonstrated that apoptosis can
be induced in the human keratinocyte cell line HaCaT by
several stimuli [12–14]. The apoptotic response is an active and
physiological form of cell death which occurs by organized
degradation of subcellular components. Although there are
other types of cell death such as necrosis, apoptosis is distin-
guished by structural and morphological features including cell
shrinkage, plasma membrane blebbing, mitochondrial swell-
ing, and chromatin condensation [15]. The apoptotic process is
usually accompanied by several changes in cellular biochem-
istry such as oligonucleosomal DNA fragmentation, caspases
activation and modiﬁcations of the levels of Bcl-2 family
members [16].
The aim of the present study was to investigate whether
apoptosis is triggered by PV-IgG binding to HaCaT kerati-
nocytes, on the basis of the speciﬁc characteristics of this
process described above.2. Materials and methods
2.1. Human sera
Serum samples were obtained from a PV patient and a normal human
donor. The PV patient exhibited classical active mucocutaneous dis-
ease, conﬁrmed by typical histological features and a titer of 1:320 of
circulating anti-ICS antibodies. Sera from patient and control were
tested by indirect IF using monkey esophagus as a tissue substrate. The
presence of anti-Dsg1 and anti-Dsg3 autoantibodies was tested by en-
zyme-linked immunoadsorbent assay (ELISA) in the serum of the do-
nors. Increased levels, expressed as index value (IV), of Dsg1 and Dsg3
immunoreactivity were found in the mucocutaneous PV patient, with
values of 75.3 5.2 and 82.5 8.1, respectively, as compared to a
healthy volunteer (1.4 0.5 for Dsg1 and 0.8 0.3 for Dsg3).
2.2. Cell culture
HaCaT cells, a human immortalized keratinocyte cell line, were a
gift from Professor N. Fusenig (Heidelberg, Germany). Cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum, penicillin (100 U/ml) and strep-
tomycin (100 lg/ml) in a 5% CO2 humidiﬁed atmosphere.
Subconﬂuent cultures maintained in serum-free medium were used in
all the experiments.blished by Elsevier B.V. All rights reserved.
Fig. 1. Western blot analysis of the immunoprecipitated extracts from
HaCaT cells obtained with an anti-plakoglobin antibody. (A) Immu-
noreactivity of IgG puriﬁed from a patient with mucocutaneous PV
(PV-IgG). (B) Identiﬁcation of Plkg after stripping of the same blot.
Fig. 2. IF staining of cytoskeletal proteins in HaCaT keratinocytes.
Cells were treated for 24 h with 2.0 mg/ml of IgG puriﬁed from a
healthy donor (N-IgG) or puriﬁed from a patient with mucocutaneous
PV (PV-IgG). After treatment, cells, including untreated controls, were
incubated with an antibody anti-cytokeratin as described in Section 2.
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IgG fractions from PV patients (PV-IgG) or normal donors (N-IgG)
were obtained by precipitation with 50% ammonium sulfate followed
by aﬃnity chromatography on Staphylococcus protein A conjugated
to agarose beads. Bound IgG was eluted with 0.2 M glycine/HCl, pH 3,
dialyzed extensively against phosphate buﬀered saline (PBS), concen-
trated by ultraﬁltration (Amicon), ﬁlter-sterilized, and stored at )70 C
until use. The IgG concentration in each fraction was estimated by
nephelometry using goat anti-human IgG (Beckman Array 360 Sys-
tem). PV-IgG and N-IgG fractions were labeled with FITC and tested
in preliminary binding studies to determine the optimal IgG doses for
the experiments.
2.4. ELISA
The reactivity of test sera with the extracellular portions of the Dsg1
or Dsg3 peptide sequences, that contain pathogenic epitopes of the PV
antigens, was determined using Dsg1 and Dsg3-coated ELISA plates
purchased from MBL (Nagoya, Japan), and following the protocol
provided by the manufacturer. All serum samples were tested in
triplicate and the results were expressed as IVs, calculated as follows:
IV¼ (ODsample )ODnegative control)/(ODpositive control )ODnegative control) 100.
As recommended by the manufacturer, a serum sample was considered
to be positive for Dsg1 or Dsg3 antibody if the IV exceeded 20.
2.5. Western blot analysis
HaCaT cells were incubated in the presence or absence of PV-IgG or
N-IgG during 8 h. Western blot analysis of cell lysates was carried out
after SDS–PAGE gels were transferred onto nitrocellulose membranes
(Amersham). Membranes were incubated with a polyclonal rabbit
antibody, anti-human Bcl-2 (Santa Cruz), or monoclonal antibodies,
anti-human Bax, (Santa Cruz), or anti-human procaspase-3 (Trans-
duction Laboratories), for 1 h at room temperature at a 1:2000 dilu-
tion. Membranes were washed and incubated for 1 h at room
temperature with 1:10 000 donkey anti-rabbit (Promega) or sheep anti-
mouse immunoglobulin horseradish peroxidase conjugated (Amer-
sham), for polyclonal or monoclonal antibodies, respectively. Bound
antibodies were detected by autoradiography with enhanced chemilu-
minescence with ECL-Plus (Amersham Pharmacia Biotech). Equiva-
lent loading was conﬁrmed by Coomassie staining of an identical gel.
2.6. Immunoprecipitation of HaCaT keratinocytes extracts
Sub-conﬂuent HaCaT keratinocytes were washed and harvested.
After sonication (ﬁve 5 s periods), cell homogenates were centrifugated
and the pellet was solubilized in a buﬀer containing 10% (wt/vol)
glycerol and 1% (wt/vol) Triton X-100, and stored at )70 C. Protein
extracts were immunoprecipitated with anti-plakoglobin antibody
(Santa Cruz) and protein A–Sepharose (Sigma) overnight at 4 C.
Proteins were released from the beads by heating at 95 C in Laemmli
sample buﬀer for 5 min and separated on discontinued SDS–poly-
acrylamide gels. Blots of immunoprecipitated samples were incubated
with 50 lg/ml of puriﬁed PV-IgG diluted 1:2000 for 2 h at room
temperature and then with a goat anti-human antibody (Sigma) diluted
1:10 000. After stripping, the membrane was incubated for 2 h at room
temperature with an anti-plakoglobin antibody (Santa Cruz) diluted
1:2000 and with a donkey anti-goat antibody (Santa Cruz) diluted
1:10 000.
2.7. IF microscopy
Cells were grown directly on glass coverslips and incubated in the
presence or absence of 2.0 mg/ml of PV-IgG or N-IgG. After 24 h,
HaCaT cells were rinsed with PBS at room temperature and dipped for
7 min in )20 C methanol. Fixed cells were incubated with a mono-
clonal anti-human keratin antibody (LP34 clon, DAKO) at a 1:20 PBS
dilution for 45 min and then incubated with a rabbit anti-mouse IgG-
FITC (DAKO) at a 1:20 PBS dilution for 45 min. Coverslips were
washed in PBS and mounted over glass slides in 50% glycerol in PBS.
2.8. Microscopic analysis
Morphologic examination of nuclei was performed using ﬂuores-
cence microscopy. Cells were grown directly on glass coverslips and
incubated in the presence or absence of 1.0 mg/ml of puriﬁed PV-IgG
or N-IgG, during 8 h. Thereafter, cells were ﬁxed with )20 C cold
methanol for 8 min, washed in PBS for 10 min, incubated with 5%
BSA in PBS for 10 min, washed three times and stained by Hoechst33342 (50 lg/ml) (Sigma) in PBS for 30 min. Coverslips were washed
three times in PBS and mounted over glass slides in 50% glycerol in
PBS.
2.9. Determination of oligonucleosomal (histone-associated) DNA
fragments
The presence of soluble histone–DNA complexes was measured by
the Cell Death Detection Assay (Boehringer Mannheim). Cells were
seeded on 24-well plates and 8 h after addition of N-IgG or PV-IgG, or
10 lg/ml camptothecin (Sigma), supernatant was discarded and cell
death ELISA assays were performed according to the manufacturer’s
instructions. Speciﬁc enrichment of mono- and oligonucleosomes re-
leased into the cytoplasm [Enrichment Factor, (EF)] was calculated as
the ratio between the absorbance of the sample and the absorbance of
the corresponding control sample (untreated cells).
2.10. Statistical analysis
The data were analyzed using the Kruskal–Wallis test to determine
diﬀerences between all independent groups. When signiﬁcant
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were tested using the Mann–Whitney U test.3. Results and discussion
3.1. Characterization of IgG antibodies from a mucocutaneous
PV patient
Immunoprecipitation of HaCaT keratinocytes extracts with
an antibody against plakoglobin (Plkg) was used to identify
the immunoreactivity of the autoantibodies obtained from a
mucocutaneous PV patient (PV-IgG). Western blot analysis of
immunocomplexes-containing samples with PV-IgG revealed
the presence of three main immunoreactive bands, corre-
sponding to 160, 130 and 85 kDa molecular weights (Fig. 1A).
The two higher bands could contain Dsg1 and Dsg3, respec-
tively, since their molecular weights were coincident and the
presence of anti-Dsg1 and anti-Dsg3 antibodies had been
already determined by ELISA (see Section 2). Although Dsg1Fig. 3. Apoptosis of HaCaT keratinocytes induced by IgG from a mucocut
Hoechst 33342. Cells were incubated for 8 h with 1.0 mg/ml IgG puriﬁed fro
(PV-IgG). Original magniﬁcation 1000. (B) Dose–response apoptotic eﬀect
with the indicated concentrations of N-IgG or PV-IgG. Treatment with 10 lg
of the apoptotic eﬀect of PV-IgG. HaCaT keratinocytes were treated with 1.0
of oligonucleosomal fragments in cytoplasmic extracts. Oligonucleosomal frag
represents the meanS.D. of quadruplicate determinations from at least this the autoantigen characteristic of pemphigus foliaceus, it is
now accepted that 25–66% of the patients with PV present
antibodies anti-Dsg1, together with the speciﬁc PV autoanti-
bodies anti-Dsg3 [17,18]. In fact, the detection of both anti-
bodies in the serum of the PV patient agreed with his diagnosis
of mucocutaneous PV, which is characterized by the presence
of anti-Dsg1 and anti-Dsg3 [19].
Binding of PV-IgG autoantibodies to Plkg was assessed by
Western blot analysis using an anti-plakoglobin antibody after
stripping of the blot (Fig. 1B). Previous immunoprecipitation
studies had detected the presence of anti-plakoglobin anti-
bodies in the serum of PV patients [4]. Plkg plays an important
role in the assembling of desmosomes and their interaction
with intermediate ﬁlaments of keratin [20]. Interestingly, ke-
ratinocytes derived from Plkg knock-out mice are resistant to
the pathogenic eﬀect of PV antibodies, suggesting that the
linkage of desmosomal Dsg3 to the cytoskeleton via Plkg
might have a central role in the molecular events leading to
acantholysis [21].aneous PV patient. (A) Nuclei staining of HaCaT keratinocytes using
m a healthy donor (N-IgG) or from a patient with mucocutaneous PV
of PV-IgG on HaCaT cells. HaCaT keratinocytes were treated for 8 h
/ml camptothecin was used as a positive control. (C) Time course study
mg/ml of PV-IgG fractions. Apoptosis was measured as accumulation
ments content was expressed as EF, as described in Section 2. Each bar
ree independent experiments (*P < 0:05, **P < 0:01, vs control).
Fig. 4. Role of caspase-3 in the apoptosis of HaCaT cells induced by
PV-IgG. (A) Western blot analysis of procaspase-3 levels in HaCaT
keratinocytes untreated or treated for 8 h with N-IgG or PV-IgG (0.5
and 1.0 mg/ml). (B) Determination of oligonucleosomal fragments in
cytoplasmic extracts from HaCaT keratinocytes incubated in control
medium or in the presence of either N-IgG or mucocutaneous PV-IgG,
after pretreatment with the caspase-3 inhibitor Ac-DEVD-CHO (30
lg/ml) during 30 min, when indicated. HaCaT keratinocytes were
treated with 0.5 and 1.0 mg/ml N-IgG or PV-IgG for 8 h. Oligonu-
cleosomal fragments content was expressed as EF, as described in
Section 2. Each bar represents the mean S.D. of quadruplicate de-
terminations from at least three independent experiments (*P < 0:05,
**P < 0:01, vs control).
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keratinocytes
IF experiments performed in cultured HaCaT keratinocytes
showed that incubation with PV-IgG induced speciﬁc changes
in intercellular unions. When compared to untreated cells
(Fig. 2A), or cells incubated with N-IgG (Fig. 2B), PV-IgG-
treated cells presented loss of cell–cell interactions (Fig. 2C).
The main histopathological characteristic of PV is acantholysis
of epidermis provoked by the disruption of keratinocyte in-
tercellular interactions. This disruption seems to be a conse-
quence of signaling pathways triggered by the binding of
PV-IgG antibodies to keratinocytes, as has been shown by
diﬀerent in vivo and in vitro studies [22–24]. Therefore, PV-
IgG antibodies were able to produce in cultured HaCaT
keratinocytes an eﬀect similar to the features observed in an-
imal models of PV and human patients aﬀected by this disease.
In the following experiments, we used this cell line to analyze
other possible eﬀects that PV-IgG could cause on human
epidermal cells in PV disease.
3.3. Apoptotic eﬀect of PV-IgG on HaCaT keratinocytes
We investigated whether PV-IgG induces the apoptotic re-
sponse in HaCaT cells, which are susceptible to apoptosis
caused by other inducers [12,25]. For this purpose, two dif-
ferent experimental approaches were used: detection of nuclear
changes characteristic of apoptosis by staining of the cells with
the ﬂuorescent probe Hoechst 3342, and determination of ol-
igonucleosomal fragments of DNA accumulated in cytoplas-
mic fractions as a consequence of the DNA fragmentation that
occurs during the apoptotic process. As shown in Fig. 3A, PV-
IgG-treated cells presented chromatin condensation that was
not observed in untreated cells (control), or was observed only
in few of the cells incubated with IgG from a healthy donor
(N-IgG). On the other hand, PV-IgG induced internucleoso-
mal DNA fragmentation in a dose-dependent manner in the
concentration range from 0.1 to 1.0 mg/ml, with maximum
values of 2.5-fold increase (Fig. 3B). N-IgG was also capable
to provoke a slight increase in cytoplasmic oligonucleosomal
content at a 1.0 mg/ml concentration, probably due to the
binding of IgG to the FcR present in keratinocytes [26]. In-
deed, binding of IgG to FcR in other cell types has been
previously shown to induce apoptosis [27].
In additional experiments using IgG fractions from another
patient aﬀected by mucocutaneous PV, we also observed the
capacity of these samples to cause apoptosis. However, the
apoptotic eﬀect was not observed with IgG fractions from
mucous PV patients, indicating that autoantibodies against
antigens other than Dsg3, not present in the mucous PV sera,
were required to cause apoptosis (data not shown).
In time course studies, apoptosis induced by IgG from a
mucocutaneous PV patient was only observed after 6 h of
exposure of the cells with the autoantibodies. Increased levels
of apoptosis were obtained at diﬀerent time points of treat-
ment between 6 and 12 h with the autoantibodies (Fig. 3C).
3.4. Mechanisms of apoptosis induced by PV-IgG in HaCaT
keratinocytes
Caspases are key mediators in apoptosis of diﬀerent cell
types provoked by most apoptotic inducers [28]. Caspase-3 is
an eﬀector caspase that causes the cleavage of several proteins,
such as PARP, DFF45, lamins, etc. [29,30]. The involvement
of caspase-3 in the apoptotic process induced by IgG from amucocutaneous PV patient in HaCaT cells was assessed by
analysis of the activation of this enzyme by proteolysis of its
inactive form, procaspase-3. Immunodetection by Western
blot of the levels of procaspase-3 showed that a decrease in this
form was produced by treatment of HaCaT cells with 0.5 or
1.0 mg/ml PV-IgG, indicating an increase of its proteolytic
activity (Fig. 4A). These results were conﬁrmed by pretreat-
ment of HaCaT cells with the caspase-3 inhibitor Ac-DVED-
CHO. The accumulation of oligonucleosomal cytosolic
fragments induced by PV-IgG was totally prevented by this
pretreatment (Fig. 4B).
The susceptibility of cells to apoptosis is controlled by the
ratio of pro-apoptotic and anti-apoptotic members of Bcl-2
family proteins. It has been demonstrated that high levels of Bcl-
2 protect HaCaT keratinocytes from apoptotic stimuli [31,32]
and that Bax protein is enhanced by treatment of this same cell
linewith some apoptosis inducers [33]. In our experiments, levels
of the pro-apoptotic protein Bax and the anti-apoptotic protein
Bcl-2 were determined byWestern blot.We found that PV-IgG-
treated HaCaT cells presented increased levels of Bax and de-
creased levels of Bcl-2 at the two concentrations tested, as
compared to untreated cells (Fig. 5). As expected, N-IgG pro-
duced a slight eﬀect on the apoptotic parameters analyzed only
at higher concentration (Figs. 4A and 5B).
In the present work, apoptosis induction of human HaCaT
keratinocytes by IgG autoantibodies obtained from a patient
with mucocutaneous PV has been assessed. In epidermis ap-
optosis plays an important role in maintaining homeostasis in
physiological situations, and also disturbed apoptosis is
Fig. 5. Western blot analysis of Bax and Bcl-2 proteins in HaCaT
keratinocytes incubated in the presence or absence of either N-IgG or
PV-IgG. HaCaT keratinocytes were treated for 8 h with 0.5 mg/ml (A)
or 1.0 mg/ml (B) of N-IgG and PV-IgG. b-Actin was used as a control
for loading.
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involvement of Fas-L-induced apoptosis in the development of
acantholysis in PV has been previously shown [34]. The results
obtained in this study suggest that PV-IgG autoantibodies
could contribute to the pathogenesis of mucocutaneous PV by
triggering apoptosis of epidermal keratinocytes. Dsg3 can in
fact be cleaved by caspase-3 [35], also pointing to the involve-
ment of apoptosis in PV development. In the same way, Nguyen
et al. [36] have recently shown that the anti-acantholytic eﬀect
of methylprednisolone is well correlated with increased ex-
pression of several adhesion proteins, including Dsg3.
The contradictory results obtained by various investigators,
related to the involvement of diﬀerent pemphigus autoanti-
bodies in acantholysis induction [37,38], might reﬂect that
apoptosis triggered by several alternative inducers, including
autoantibodies and other factors present in PV patients sera
such as the Fas-L, could participate in the subsequent acan-
tholytic process associated with these types of diseases.
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